Tags: icahn | amylin | drug | pharma | M&A

Icahn: Amylin Should Put Itself Up for Sale

Tuesday, 03 Apr 2012 07:12 PM

Amylin Pharmaceuticals Inc., which turned down a $22-a-share bid from Bristol-Myers Squibb Co. earlier this year, should pursue a sale process to get the best price for shareholders, investor Carl Icahn said.

“This company could fetch more than $22,” Icahn, who is San Diego-based Amylin’s third-largest stockholder with 14.4 million shares as of Dec. 31, said in a telephone interview today. “The company should go through a process and try to get the price they can for shareholders, and let the shareholders decide.”

© Copyright 2016 Bloomberg News. All rights reserved.

1Like our page

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

© Newsmax Media, Inc.
All Rights Reserved